AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] --
AAC Accepts, published online ahead of print on 25 May 2007
This Article
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
AAC.00256-07v1
51/8/3001    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Strahilevitz, J.
Right arrow Articles by Robicsek, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Strahilevitz, J.
Right arrow Articles by Robicsek, A.

 Previous Article  |  Next Article 

Antimicrob. Agents Chemother. doi:10.1128/AAC.00256-07
Copyright (c) 2007, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.

Changes in qnr prevalence and fluoroquinolone resistance in clinical isolates of Klebsiella pneumoniae and Enterobacter spp.; 1990-2005

Jacob Strahilevitz*, Dalia Engelstein, Amos Adler, Violeta Temper, Allon E. Moses, Colin Block, and Ari Robicsek

Department of Clinical Microbiology and Infectious Diseases, Hadassah-Hebrew University, Jerusalem, 91120; Department of Medicine, Evanston Northwestern Healthcare, 2650 Ridge Ave, Evanston IL, 60201

* To whom correspondence should be addressed. Email: jstrahilevitz{at}hadassah.org.il.


   Abstract

Clinical isolates of Klebsiella pneumoniae and Enterobacter spp. collected from 1990 through 2005 at a tertiary care center were studied for qnr genes. Isolates bearing these genes emerged in the mid-1990s, coinciding with the time of rapid increase in fluoroquinolone resistance. 60% of these isolates were ciprofloxacin susceptible by CLSI breakpoints.




This article has been cited by other articles:




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2007 by the American Society for Microbiology. All rights reserved.